{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T02:41:10Z","timestamp":1790044870648,"version":"4.0.1"},"reference-count":259,"publisher":"MDPI AG","issue":"16","license":[{"start":{"date-parts":[[2024,8,17]],"date-time":"2024-08-17T00:00:00Z","timestamp":1723852800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"CNPq (National Council for Scientific and Technological Development), Brazil","award":["306547\/2020-1"],"award-info":[{"award-number":["306547\/2020-1"]}]},{"name":"CNPq (National Council for Scientific and Technological Development), Brazil","award":["403543\/2021-5"],"award-info":[{"award-number":["403543\/2021-5"]}]},{"name":"CNPq (National Council for Scientific and Technological Development), Brazil","award":["00193-00000724\/2021-30"],"award-info":[{"award-number":["00193-00000724\/2021-30"]}]},{"name":"CNPq (National Council for Scientific and Technological Development), Brazil","award":["code 001"],"award-info":[{"award-number":["code 001"]}]},{"name":"FAPDF (Federal District Research Support Foundation), Brazil","award":["306547\/2020-1"],"award-info":[{"award-number":["306547\/2020-1"]}]},{"name":"FAPDF (Federal District Research Support Foundation), Brazil","award":["403543\/2021-5"],"award-info":[{"award-number":["403543\/2021-5"]}]},{"name":"FAPDF (Federal District Research Support Foundation), Brazil","award":["00193-00000724\/2021-30"],"award-info":[{"award-number":["00193-00000724\/2021-30"]}]},{"name":"FAPDF (Federal District Research Support Foundation), Brazil","award":["code 001"],"award-info":[{"award-number":["code 001"]}]},{"name":"CAPES Brazil finance graduate student scholarship","award":["306547\/2020-1"],"award-info":[{"award-number":["306547\/2020-1"]}]},{"name":"CAPES Brazil finance graduate student scholarship","award":["403543\/2021-5"],"award-info":[{"award-number":["403543\/2021-5"]}]},{"name":"CAPES Brazil finance graduate student scholarship","award":["00193-00000724\/2021-30"],"award-info":[{"award-number":["00193-00000724\/2021-30"]}]},{"name":"CAPES Brazil finance graduate student scholarship","award":["code 001"],"award-info":[{"award-number":["code 001"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Parkinson\u2019s disease (PD) is the second most common neurodegenerative disease globally. Current drugs only alleviate symptoms without halting disease progression, making rodent models essential for researching new therapies and understanding the disease better. However, selecting the right model is challenging due to the numerous models and protocols available. Key factors in model selection include construct, face, and predictive validity. Construct validity ensures the model replicates pathological changes seen in human PD, focusing on dopaminergic neurodegeneration and a-synuclein aggregation. Face validity ensures the model\u2019s symptoms mirror those in humans, primarily reproducing motor and non-motor symptoms. Predictive validity assesses if treatment responses in animals will reflect those in humans, typically involving classical pharmacotherapies and surgical procedures. This review highlights the primary characteristics of PD and how these characteristics are validated experimentally according to the three criteria. Additionally, it serves as a valuable tool for researchers in selecting the most appropriate animal model based on established validation criteria.<\/jats:p>","DOI":"10.3390\/ijms25168971","type":"journal-article","created":{"date-parts":[[2024,8,19]],"date-time":"2024-08-19T07:37:21Z","timestamp":1724053041000},"page":"8971","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Construct, Face, and Predictive Validity of Parkinson\u2019s Disease Rodent Models"],"prefix":"10.3390","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9253-2770","authenticated-orcid":false,"given":"Rayanne Poletti","family":"Guimar\u00e3es","sequence":"first","affiliation":[{"name":"Neuropharma Lab, Department of Physiological Sciences, Institute of Biological Sciences, University of Bras\u00edlia, Bras\u00edlia 70910-900, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0049-590X","authenticated-orcid":false,"given":"Maria Clara Souza de","family":"Resende","sequence":"additional","affiliation":[{"name":"Neuropharma Lab, Department of Physiological Sciences, Institute of Biological Sciences, University of Bras\u00edlia, Bras\u00edlia 70910-900, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel Mesquita","family":"Tavares","sequence":"additional","affiliation":[{"name":"Neuropharma Lab, Department of Physiological Sciences, Institute of Biological Sciences, University of Bras\u00edlia, Bras\u00edlia 70910-900, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caio","family":"Belardinelli de Azevedo","sequence":"additional","affiliation":[{"name":"Neuropharma Lab, Department of Physiological Sciences, Institute of Biological Sciences, University of Bras\u00edlia, Bras\u00edlia 70910-900, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7164-6704","authenticated-orcid":false,"given":"Miguel Cesar Merino","family":"Ruiz","sequence":"additional","affiliation":[{"name":"Neuropharma Lab, Department of Physiological Sciences, Institute of Biological Sciences, University of Bras\u00edlia, Bras\u00edlia 70910-900, Brazil"},{"name":"Neurological Rehabilitation Unit, Sarah Network of Rehabilitation Hospitals, Bras\u00edlia 70335-901, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6849-6001","authenticated-orcid":false,"given":"M\u00e1rcia Renata","family":"Mortari","sequence":"additional","affiliation":[{"name":"Neuropharma Lab, Department of Physiological Sciences, Institute of Biological Sciences, University of Bras\u00edlia, Bras\u00edlia 70910-900, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,8,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1007\/s00702-017-1686-y","article-title":"Epidemiology of Parkinson\u2019s disease","volume":"124","author":"Tysnes","year":"2017","journal-title":"J. Neural Transm."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1136\/jnnp.51.6.745","article-title":"The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson\u2019s disease","volume":"51","author":"Gibb","year":"1988","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"200","DOI":"10.3934\/Neuroscience.2023017","article-title":"Depletion of dopamine in Parkinson\u2019s disease and relevant therapeutic options: A review of the literature","volume":"10","author":"Ramesh","year":"2023","journal-title":"AIMS Neurosci."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Sarkar, S., Raymick, J., and Imam, S. (2016). Neuroprotective and Therapeutic Strategies against Parkinson\u2019s Disease: Recent Perspectives. Int. J. Mol. Sci., 17.","DOI":"10.3390\/ijms17060904"},{"key":"ref_5","unstructured":"Kouli, A., Torsney, K.M., and Kuan, W.-L. (2018). Parkinson\u2019s Disease: Etiology, Neuropathology, and Pathogenesis. Parkinson\u2019s Disease: Pathogenesis and Clinical Aspects, Codon Publications."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/ene.14108","article-title":"Parkinson disease","volume":"27","author":"Balestrino","year":"2020","journal-title":"Eur. J. Neurol."},{"key":"ref_7","first-page":"e62923","article-title":"The 6-hydroxydopamine rat model of Parkinson\u2019s disease","volume":"176","author":"Ribeiro","year":"2021","journal-title":"J. Vis. Exp."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Kin, K., Yasuhara, T., Kameda, M., and Date, I. (2019). Animal Models for Parkinson\u2019s Disease Research: Trends in the 2000s. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20215402"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"223","DOI":"10.14336\/AD.2020.0331","article-title":"Comprehensive Perspectives on Experimental Models for Parkinson\u2019s Disease","volume":"12","author":"Ke","year":"2021","journal-title":"Aging Dis."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/BF03033569","article-title":"Model fusion, the next phase in developing animal models for Parkinson\u2019s disease","volume":"11","author":"Langston","year":"2007","journal-title":"Neurotox. Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/0278-5846(86)90051-5","article-title":"Validation criteria for animal models of human mental disorders: Learned helplessness as a paradigm case","volume":"10","author":"Willner","year":"1986","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"ref_12","first-page":"e3234","article-title":"Development of a Unilaterally-lesioned 6-OHDA Mouse Model of Parkinson\u2019s Disease","volume":"60","author":"Thiele","year":"2012","journal-title":"J. Vis. Exp."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.expneurol.2012.02.012","article-title":"Comparison of the behavioural and histological characteristics of the 6-OHDA and \u03b1-synuclein rat models of Parkinson\u2019s disease","volume":"235","author":"Decressac","year":"2012","journal-title":"Exp. Neurol."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Sl\u00e9zia, A., Heged\u00fcs, P., Rusina, E., Lengyel, K., Solari, N., Kaszas, A., Bal\u00e1zsfi, D., Botzanowski, B., Acerbo, E., and Missey, F. (2023). Behavioral, neural and ultrastructural alterations in a graded-dose 6-OHDA mouse model of early-stage Parkinson\u2019s disease. Sci. Rep., 13.","DOI":"10.1038\/s41598-023-46576-0"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Gubinelli, F., Sarauskyte, L., Venuti, C., Kulacz, I., Cazzolla, G., Negrini, M., Anwer, D., Vecchio, I., Jakobs, F., and Manfredsson, F.P. (2023). Characterisation of functional deficits induced by AAV overexpression of alpha-synuclein in rats. Curr. Res. Neurobiol., 4.","DOI":"10.1016\/j.crneur.2022.100065"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1759091418777438","DOI":"10.1177\/1759091418777438","article-title":"Neurotoxin-Induced Animal Models of Parkinson Disease: Pathogenic Mechanism and Assessment","volume":"10","author":"Zeng","year":"2018","journal-title":"ASN Neuro"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Li, Y., Yin, Q., Wang, B., Shen, T., Luo, W., and Liu, T. (2022). Preclinical reserpine models recapitulating motor and non-motor features of Parkinson\u2019s disease: Roles of epigenetic upregulation of alpha-synuclein and autophagy impairment. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.944376"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1111\/bpa.12253","article-title":"Molecular, Neurochemical, and Behavioral Hallmarks of Reserpine as a Model for Parkinson\u2019s Disease: New Perspectives to a Long-Standing Model","volume":"25","author":"Santos","year":"2015","journal-title":"Brain Pathol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"NS20210026","DOI":"10.1042\/NS20210026","article-title":"Animal models of Parkinson\u2019s disease: A guide to selecting the optimal model for your research","volume":"5","author":"Lama","year":"2021","journal-title":"Neuronal Signal."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.nbd.2009.01.016","article-title":"A highly reproducible rotenone model of Parkinson\u2019s disease","volume":"34","author":"Cannon","year":"2009","journal-title":"Neurobiol. Dis."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1006\/exnr.2002.8072","article-title":"Subcutaneous Rotenone Exposure Causes Highly Selective Dopaminergic Degeneration and \u03b1-Synuclein Aggregation","volume":"179","author":"Sherer","year":"2003","journal-title":"Exp. Neurol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/s41531-023-00561-6","article-title":"Transient exposure to rotenone causes degeneration and progressive parkinsonian motor deficits, neuroinflammation, and synucleinopathy","volume":"9","author":"Webb","year":"2023","journal-title":"NPJ Parkinson\u2019s Dis."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1006\/nbdi.2002.0507","article-title":"Environmental Risk Factors and Parkinson\u2019s Disease: Selective Degeneration of Nigral Dopaminergic Neurons Caused by the Herbicide Paraquat","volume":"10","author":"McCormack","year":"2002","journal-title":"Neurobiol Dis"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1111\/j.1471-4159.2005.03088.x","article-title":"Role of Oxidative Stress in Paraquat-Induced Dopaminergic Cell Degeneration","volume":"93","author":"McCormack","year":"2005","journal-title":"J. Neurochem."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"32626","DOI":"10.1074\/jbc.M404596200","article-title":"The Herbicide Paraquat Induces Dopaminergic Nigral Apoptosis through Sustained Activation of the JNK Pathway","volume":"279","author":"Peng","year":"2004","journal-title":"J. Biol. Chem."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1523\/JNEUROSCI.23-08-03095.2003","article-title":"\u03b1-Synuclein Overexpression Protects against Paraquat-Induced Neurodegeneration","volume":"23","author":"McCormack","year":"2003","journal-title":"J. Neurosci."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1074\/jbc.C100560200","article-title":"The Herbicide Paraquat Causes Up-Regulation and Aggregation of \u03b1-Synuclein in Mice: PARAQUAT AND \u03b1-SYNUCLEIN","volume":"277","author":"McCormack","year":"2002","journal-title":"J. Biol. Chem."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1126\/science.1227157","article-title":"Pathological \u03b1-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice","volume":"338","author":"Luk","year":"2012","journal-title":"Science"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"3373","DOI":"10.1016\/j.celrep.2016.08.053","article-title":"Molecular and Biological Compatibility with Host Alpha-Synuclein Influences Fibril Pathogenicity","volume":"16","author":"Luk","year":"2016","journal-title":"Cell Rep."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1038\/s41593-019-0457-5","article-title":"Spread of \u03b1-Synuclein Pathology through the Brain Connectome Is Modulated by Selective Vulnerability and Predicted by Network Analysis","volume":"22","author":"Henderson","year":"2019","journal-title":"Nat. Neurosci."},{"key":"ref_31","first-page":"53670","article-title":"Development of an Alpha-Synuclein Based Rat Model for Parkinson\u2019s Disease via Stereotactic Injection of a Recombinant Adeno-Associated Viral Vector","volume":"2016","author":"Casteels","year":"2016","journal-title":"J. Vis. Exp."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.bbi.2022.01.007","article-title":"Neurodegeneration by \u03b1-Synuclein-Specific T Cells in AAV-A53T-\u03b1-Synuclein Parkinson\u2019s Disease Mice","volume":"101","author":"Karikari","year":"2022","journal-title":"Brain Behav. Immun."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s00401-019-02023-x","article-title":"Depopulation of Dense \u03b1-Synuclein Aggregates Is Associated with Rescue of Dopamine Neuron Dysfunction and Death in a New Parkinson\u2019s Disease Model","volume":"138","author":"Wegrzynowicz","year":"2019","journal-title":"Acta Neuropathol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1126\/science.287.5456.1265","article-title":"Dopaminergic loss and inclusion body formation in alpha-synuclein mice: Implications for neurodegenerative disorders","volume":"287","author":"Masliah","year":"2000","journal-title":"Science"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s13311-012-0104-2","article-title":"A Progressive Mouse Model of Parkinson\u2019s Disease: The Thy1-ASyn (\u201cLine 61\u201d) Mice","volume":"9","author":"Chesselet","year":"2012","journal-title":"Neurotherapeutics"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1002\/jnr.10231","article-title":"Differential Neuropathological Alterations in Transgenic Mice Expressing Alpha-Synuclein from the Platelet-Derived Growth Factor and Thy-1 Promoters","volume":"68","author":"Rockenstein","year":"2002","journal-title":"J. Neurosci. Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/0014-2999(68)90164-7","article-title":"6-Hydroxy-dopamine induced degeneration of central monoamine neurons","volume":"5","author":"Ungerstedt","year":"1968","journal-title":"Eur. J. Pharmacol."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Cenci, M.A., and Bj\u00f6rklund, A. (2020). Animal models for preclinical Parkinson\u2019s research: An update and critical appraisal. Progress in Brain Research, Elsevier B.V.","DOI":"10.1016\/bs.pbr.2020.02.003"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"103","DOI":"10.5607\/en.2015.24.2.103","article-title":"Mitochondrial Dysfunction in Parkinson\u2019s Disease","volume":"24","author":"Hattori","year":"2015","journal-title":"Exp. Neurobiol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1111\/j.1471-4159.1990.tb02325.x","article-title":"Mitochondrial Complex I Deficiency in Parkinson\u2019s Disease","volume":"54","author":"Schapira","year":"1990","journal-title":"J. Neurochem."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/0306-4522(94)90605-X","article-title":"Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxydopamine: A combined retrograde tracing and immunocytochemical study in the rat","volume":"59","author":"Sauer","year":"1994","journal-title":"Neuroscience"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/0306-4522(95)00066-R","article-title":"Dose-dependent lesions of the dopaminergic nigrostriatal pathway induced by instrastriatal injection of 6-hydroxydopamine","volume":"67","author":"Przedbroski","year":"1995","journal-title":"Neuroscience"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.neuroscience.2011.10.057","article-title":"Neurotoxin-based models of Parkinson\u2019s disease","volume":"211","author":"Perier","year":"2012","journal-title":"Neuroscience"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1046\/j.1471-4159.2001.00183.x","article-title":"The parkinsonian toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): A technical review of its utility and safety","volume":"76","author":"Przedborski","year":"2001","journal-title":"J. Neurochem."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.neures.2005.04.010","article-title":"MPTP treatment in mice does not transmit and cause Parkinsonian neurotoxicity in non-treated cagemates through close contact","volume":"52","author":"Lau","year":"2005","journal-title":"Neurosci. Res."},{"key":"ref_46","first-page":"1000","article-title":"Studies on species sensitivity to the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Part 1: Systemic administration","volume":"270","author":"Giovanni","year":"1994","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_47","first-page":"336","article-title":"Inhibition of Brain Vesicular Monoamine Transporter (VMAT2) Enhances 1-Methyl-4-phenylpyridinium Neurotoxicity In Vivo in Rat Striata","volume":"293","author":"Staal","year":"2000","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.expneurol.2006.07.001","article-title":"The risk is in the air: Intranasal administration of MPTP to rats reproducing clinical features of Parkinson\u2019s disease","volume":"202","author":"Prediger","year":"2006","journal-title":"Exp. Neurol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1007\/s12640-009-9087-0","article-title":"Single intranasal administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in C57BL\/6 mice models early preclinical phase of Parkinson\u2019s disease","volume":"17","author":"Prediger","year":"2010","journal-title":"Neurotoxic. Res."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Carta, A.R., Carboni, E., and Spiga, S. (2013). The MPTP\/Probenecid Model of Progressive Parkinson\u2019s Disease. Dopamine: Methods and Protocols, Humana Press.","DOI":"10.1007\/978-1-62703-251-3_17"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"3437","DOI":"10.1007\/s12035-018-1315-2","article-title":"Upgraded Methodology for the Development of Early Diagnosis of Parkinson\u2019s Disease Based on Searching Blood Markers in Patients and Experimental Models","volume":"56","author":"Kim","year":"2019","journal-title":"Mol. Neurobiol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1038\/cdd.2009.217","article-title":"Paraquat and Parkinson\u2019s disease","volume":"17","author":"Berry","year":"2010","journal-title":"Cell Death Differ."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.nbd.2012.06.025","article-title":"Gene-environment interactions in Parkinson\u2019s disease: Specific evidence in humans and mammalian models","volume":"57","author":"Cannon","year":"2013","journal-title":"Neurobiol. Dis."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s00204-017-2133-4","article-title":"An adverse outcome pathway for parkinsonian motor deficits associated with mitochondrial complex I inhibition","volume":"92","author":"Terron","year":"2018","journal-title":"Arch. Toxicol."},{"key":"ref_55","first-page":"2366","article-title":"Toxic influence of chronic oral administration of paraquat on nigrostriatal dopaminergic neurons in C57BL\/6 mice","volume":"122","author":"Ren","year":"2009","journal-title":"Chin. Med. J."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1016\/j.freeradbiomed.2010.02.024","article-title":"Activation of apoptosis signal-regulating kinase 1 is a key factor in paraquat-induced cell death: Modulation by the Nrf2\/Trx axis","volume":"48","author":"Soler","year":"2010","journal-title":"Free Radic. Biol. Med."},{"key":"ref_57","first-page":"658083","article-title":"Limitations of Animal Models of Parkinson\u2019s Disease","volume":"2011","author":"Potashkin","year":"2011","journal-title":"Parkinson\u2019s Dis."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Jagmag, S.A., Tripathi, N., Shukla, S.D., Maiti, S., and Khurana, S. (2016). Evaluation of Models of Parkinson\u2019s Disease. Front. Neurosci., 9.","DOI":"10.3389\/fnins.2015.00503"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/0006-8993(96)00598-7","article-title":"The dopamine-depleting effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in CD-1 mice are gender-dependent","volume":"735","author":"Freyaldenhoven","year":"1996","journal-title":"Brain Res."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.pbb.2004.04.022","article-title":"Sex dimorphisms in the neuroprotective effects of estrogen in an animal model of Parkinson\u2019s disease","volume":"78","author":"Gillies","year":"2004","journal-title":"Pharmacol. Biochem. Behav."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.neubiorev.2015.09.023","article-title":"Levels and actions of neuroactive steroids in the nervous system under physiological and pathological conditions: Sex-specific features","volume":"67","author":"Melcangi","year":"2016","journal-title":"Neurosci. Biobehav. Rev."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/26652","article-title":"The ubiquitin pathway in Parkinson\u2019s disease","volume":"395","author":"Leroy","year":"1998","journal-title":"Nature"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.neuint.2006.07.015","article-title":"Dopaminergic neuronal loss in transgenic mice expressing the Parkinson\u2019s disease-associated UCH-L1 I93M mutant","volume":"50","author":"Setsuie","year":"2007","journal-title":"Neurochem. Int."},{"key":"ref_64","unstructured":"Konnova, E.A., and Swanberg, M. (2018). Animal Models of Parkinson\u2019s Disease. Parkinson\u2019s Disease: Pathogenesis and Clinical Aspects, Codon Publications."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/1750-1326-8-44","article-title":"RAAV2\/7 vector-mediated overexpression of alpha-synuclein in mouse substantia nigra induces protein aggregation and progressive dose-dependent neurodegeneration","volume":"8","author":"Casadei","year":"2013","journal-title":"Mol. Neurodegener."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1750-1326-4-9","article-title":"\u03b1-Synuclein and neuronal cell death","volume":"4","author":"Cookson","year":"2009","journal-title":"Mol. Neurodegener."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"2804","DOI":"10.1523\/JNEUROSCI.08-08-02804.1988","article-title":"Synuclein: A neuron-specific protein localized to the nucleus and presynaptic nerve terminal","volume":"8","author":"Maroteaux","year":"1988","journal-title":"J. Neurosci."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.neuron.2009.12.023","article-title":"Increased expression of alpha-synuclein reduces neurotransmitter release by inhibiting synaptic vesicle reclustering after endocytosis","volume":"65","author":"Nemani","year":"2010","journal-title":"Neuron"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"15313","DOI":"10.1074\/jbc.M213128200","article-title":"A Broken \u03b1-Helix in Folded \u03b1-Synuclein","volume":"278","author":"Chandra","year":"2003","journal-title":"J. Biol. Chem."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s13024-020-00368-6","article-title":"Initiation and propagation of \u03b1-synuclein aggregation in the nervous system","volume":"15","author":"Hijaz","year":"2020","journal-title":"Mol. Neurodegener."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s12264-019-00433-1","article-title":"Biomarkers for Parkinson\u2019s Disease: How Good Are They?","volume":"36","author":"Li","year":"2020","journal-title":"Neurosci. Bull."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.tins.2016.09.003","article-title":"\u03b1-Synuclein-Based Animal Models of Parkinson\u2019s Disease: Challenges and Opportunities in a New Era","volume":"39","author":"Visanji","year":"2016","journal-title":"Trends Neurosci."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"G\u00f3mez-Benito, M., Granado, N., Garc\u00eda-Sanz, P., Michel, A., Dumoulin, M., and Moratalla, R. (2020). Modeling Parkinson\u2019s Disease with the Alpha-Synuclein Protein. Front. Pharmacol., 11.","DOI":"10.3389\/fphar.2020.00356"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"113887","DOI":"10.1016\/j.bbr.2022.113887","article-title":"Lateralized deficits after unilateral AAV-vector based overexpression of alpha-synuclein in the midbrain of rats on drug-free behavioral tests","volume":"429","author":"Gubinelli","year":"2022","journal-title":"Behav. Brain Res."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"303","DOI":"10.3233\/JPD-171248","article-title":"Best Practices for Generating and Using Alpha-Synuclein Pre-Formed Fibrils to Model Parkinson\u2019s Disease in Rodents","volume":"8","author":"Polinski","year":"2018","journal-title":"J. Parkinson\u2019s Dis."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1084\/jem.20112457","article-title":"Intracerebral inoculation of pathological \u03b1-synuclein initiates a rapidly progressive neurodegenerative \u03b1-synucleinopathy in mice","volume":"209","author":"Luk","year":"2012","journal-title":"J. Exp. Med."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.3233\/JPD-212847","article-title":"A Summary of Phenotypes Observed in the In Vivo Rodent Alpha-Synuclein Preformed Fibril Model","volume":"11","author":"Polinski","year":"2021","journal-title":"J. Parkinson\u2019s Dis."},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Lamontagne-Proulx, J., Coulombe, K., Morissette, M., Rieux, M., Calon, F., Di Paolo, T., and Soulet, D. (2023). Sex and Age Differences in a Progressive Synucleinopathy Mouse Model. Biomolecules, 13.","DOI":"10.3390\/biom13060977"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1038\/aps.2017.49","article-title":"Reassessment of subacute MPTP-treated mice as animal model of Parkinson\u2019s disease","volume":"38","author":"Zhang","year":"2017","journal-title":"Acta Pharmacol. Sin."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/nprot.2006.342","article-title":"Protocol for the MPTP mouse model of Parkinson\u2019s disease","volume":"2","author":"Przedborski","year":"2007","journal-title":"Nat. Protoc."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1007\/s12035-015-9179-1","article-title":"Formation and Implications of Alpha-Synuclein Radical in Maneb- and Paraquat-Induced Models of Parkinson\u2019s Disease","volume":"53","author":"Kumar","year":"2016","journal-title":"Mol. Neurobiol."},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Wills, J., Credle, J., Oaks, A.W., Duka, V., Lee, J.H., Jones, J., and Sidhu, A. (2012). Paraquat, but Not Maneb, Induces Synucleinopathy and Tauopathy in Striata of Mice through Inhibition of Proteasomal and Autophagic Pathways. PLoS ONE, 7.","DOI":"10.1371\/annotation\/6c09a04c-e565-4a34-b24e-90f084463e15"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1038\/81834","article-title":"Chronic systemic pesticide exposure reproduces features of Parkinson\u2019s disease","volume":"3","author":"Betarbet","year":"2000","journal-title":"Nat. Neurosci."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1126\/science.276.5321.2045","article-title":"Mutation in the \u03b1-Synuclein Gene Identified in Families with Parkinson\u2019s Disease","volume":"276","author":"Polymeropoulos","year":"1997","journal-title":"Science"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1126\/science.1077209","article-title":"Mutations in the DJ-1 Gene Associated with Autosomal Recessive Early-Onset Parkinsonism","volume":"299","author":"Bonifati","year":"2003","journal-title":"Science"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s13024-019-0329-1","article-title":"Alpha-Synuclein Structure and Parkinson\u2019s Disease\u2014Lessons and Emerging Principles","volume":"14","author":"Meade","year":"2019","journal-title":"Mol. Neurodegener."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1126\/science.1096284","article-title":"Hereditary Early-Onset Parkinson\u2019s Disease Caused by Mutations in PINK1","volume":"304","author":"Valente","year":"2004","journal-title":"Science"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1002\/mds.26237","article-title":"Impact of Parkinson\u2019s Disease Risk Loci on Age at Onset","volume":"30","author":"Lill","year":"2015","journal-title":"Mov. Disord."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1006\/nbdi.2001.0392","article-title":"Lack of Nigral Pathology in Transgenic Mice Expressing Human \u03b1-Synuclein Driven by the Tyrosine Hydroxylase Promoter","volume":"8","author":"Matsuoka","year":"2001","journal-title":"Neurobiol. Dis."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1111\/j.1460-9568.2010.07558.x","article-title":"Biochemical and Morphological Consequences of Human \u03b1-Synuclein Expression in a Mouse \u03b1-Synuclein Null Background","volume":"33","author":"Prasad","year":"2011","journal-title":"Eur. J. Neurosci."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1038\/s41467-018-03111-4","article-title":"C-terminal calcium binding of \u03b1-synuclein modulates synaptic vesicle interaction","volume":"9","author":"Stephens","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1002\/cbic.200800581","article-title":"Pathogenic mutations shift the equilibria of \u03b1-synuclein single molecules towards structured conformers","volume":"10","author":"Brucale","year":"2009","journal-title":"ChemBioChem"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"15227","DOI":"10.1523\/JNEUROSCI.3545-12.2012","article-title":"Systematic mutagenesis of \u03b1-synuclein reveals distinct sequence requirements for physiological and pathological activities","volume":"32","author":"Sharma","year":"2012","journal-title":"J. Neurosci."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1016\/j.parkreldis.2015.08.015","article-title":"Phenotypic spectrum of alpha-synuclein mutations: New insights from patients and cellular models","volume":"22","author":"Petrucci","year":"2016","journal-title":"Park. Relat. Disord."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1002\/mds.25499","article-title":"The many faces of alpha-synuclein mutations","volume":"28","author":"Kasten","year":"2013","journal-title":"Mov. Disord."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"21856","DOI":"10.1074\/jbc.M114.553297","article-title":"The H50Q mutation enhances \u03b1\u03b1-synuclein aggregation, secretion, and toxicity","volume":"289","author":"Khalaf","year":"2014","journal-title":"J. Biol. Chem."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.brainres.2018.01.010","article-title":"Parkinson\u2019s disease from the gut","volume":"1693","author":"Liddle","year":"2018","journal-title":"Brain Res."},{"key":"ref_98","first-page":"205","article-title":"Alpha-synuclein A30P point-mutation generates age-dependent nigrostriatal deficiency in mice","volume":"59","author":"Plaas","year":"2008","journal-title":"J. Physiol. Pharmacol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1093\/hmg\/ddq038","article-title":"Extensive enteric nervous system abnormalities in mice transgenic for artificial chromosomes containing Parkinson disease-associated \u03b1-synuclein gene mutations precede central nervous system changes","volume":"19","author":"Kuo","year":"2010","journal-title":"Hum. Mol. Genet."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1002\/ana.10795","article-title":"The New Mutation, E46K, of \u03b1-Synuclein Causes Parkinson and Lewy Body Dementia","volume":"55","author":"Zarranz","year":"2004","journal-title":"Ann. Neurol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"109333","DOI":"10.1016\/j.celrep.2021.109333","article-title":"Altered conformation of \u03b1-synuclein drives dysfunction of synaptic vesicles in a synaptosomal model of Parkinson\u2019s disease","volume":"36","author":"Viennet","year":"2021","journal-title":"Cell Rep."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1111\/febs.13249","article-title":"Parkin structure and function","volume":"282","author":"Seirafi","year":"2015","journal-title":"FEBS J."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"2174","DOI":"10.1073\/pnas.0409598102","article-title":"Parkin-deficient mice are not a robust model of parkinsonism","volume":"102","author":"Perez","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/33416","article-title":"Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism","volume":"392","author":"Kitada","year":"1998","journal-title":"Nature"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1083\/jcb.200809125","article-title":"Parkin Is Recruited Selectively to Impaired Mitochondria and Promotes Parkin is recruited selectively to impaired mitochondria and promotes their autophagy","volume":"183","author":"Narendra","year":"2008","journal-title":"J. Cell Biol."},{"key":"ref_106","doi-asserted-by":"crossref","unstructured":"Narendra, D.P., Jin, S.M., Tanaka, A., Suen, D.F., Gautier, C.A., Shen, J., Cookson, M.R., and Youle, R.J. (2010). PINK1 is selectively stabilized on impaired mitochondria to activate Parkin. PLoS Biol., 8.","DOI":"10.1371\/journal.pbio.1000298"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1126\/science.1249161","article-title":"PINK1 loss-of-function mutations affect mitochondrial complex I activity via NdufA10 ubiquinone uncoupling","volume":"344","author":"Morais","year":"2014","journal-title":"Science"},{"key":"ref_108","doi-asserted-by":"crossref","unstructured":"Pridgeon, J.W., Olzmann, J.A., Chin, L.S., and Li, L. (2007). PINK1 protects against oxidative stress by phosphorylating mitochondrial chaperone TRAP1. PLoS Biol., 5.","DOI":"10.1371\/journal.pbio.0050172"},{"key":"ref_109","first-page":"229","article-title":"Loss-of-function rodent models for parkin and PINK1","volume":"1","author":"Heeman","year":"2011","journal-title":"J. Park. Dis."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1038\/emboj.2012.170","article-title":"Mitochondrial dysfunction in Parkinson\u2019s disease: Molecular mechanisms and pathophysiological consequences","volume":"31","author":"Exner","year":"2012","journal-title":"EMBO J."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"114771","DOI":"10.1016\/j.expneurol.2024.114771","article-title":"Aging accelerates locomotor decline in PINK1 knockout rats in association with decreased nigral, but not striatal, dopamine and tyrosine hydroxylase expression","volume":"376","author":"Soto","year":"2024","journal-title":"Exp. Neurol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1136\/jnnp.55.2.138","article-title":"Bilateral olfactory dysfunction in early stage treated and untreated idiopathic Parkinson\u2019s disease","volume":"55","author":"Doty","year":"1992","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.expneurol.2012.01.002","article-title":"Pink1-deficiency in mice impairs gait, olfaction and serotonergic innervation of the olfactory bulb","volume":"235","author":"Glasl","year":"2012","journal-title":"Exp. Neurol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"21418","DOI":"10.1074\/jbc.M413955200","article-title":"Age-dependent motor deficits and dopaminergic dysfunction in DJ-1 null mice","volume":"280","author":"Chen","year":"2005","journal-title":"J. Biol. Chem."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1093\/brain\/awt192","article-title":"Disease duration and the integrity of the nigrostriatal system in Parkinson\u2019s disease","volume":"136","author":"Kordower","year":"2013","journal-title":"Brain"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"5215","DOI":"10.1073\/pnas.0501282102","article-title":"Hypersensitivity of DJ-1-deficient mice to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrindine (MPTP) and oxidative stress","volume":"102","author":"Kim","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"14807","DOI":"10.1073\/pnas.0703219104","article-title":"DJ-1 gene deletion reveals that DJ-1 is an atypical peroxiredoxin-like peroxidase","volume":"104","author":"Perier","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s10863-019-09798-4","article-title":"Role of DJ-1 in the mechanism of pathogenesis of Parkinson\u2019s disease","volume":"51","author":"Dolgacheva","year":"2019","journal-title":"J. Bioenerg. Biomembr."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1136\/jmedgenet-2019-106283","article-title":"Genetic variability and potential effects on clinical trial outcomes: Perspectives in Parkinson\u2019s disease","volume":"57","author":"Leonard","year":"2020","journal-title":"J. Med. Genet."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s42466-019-0033-1","article-title":"An omics-based strategy using coenzyme Q10 in patients with Parkinson\u2019s disease: Concept evaluation in a double-blind randomized placebo-controlled parallel group trial","volume":"1","author":"Prasuhn","year":"2019","journal-title":"Neurol. Res. Pract."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1001\/archpsyc.1969.01740200112015","article-title":"Animal Model of Depression: I. Review of Evidence: Implications for Research","volume":"21","author":"McKinney","year":"1969","journal-title":"Arch. Gen. Psychiatry"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1037\/0021-843X.87.1.49","article-title":"Learned helplessness in humans: Critique and reformulation","volume":"87","author":"Abramson","year":"1978","journal-title":"J. Abnorm. Psychol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/0361-9230(91)90245-F","article-title":"Hypokinesia, rigidity, and tremor induced by hypothalamic 6-OHDA lesions in the rat","volume":"26","author":"Jolicoeur","year":"1991","journal-title":"Brain Res. Bull."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/0306-4522(96)00418-6","article-title":"Influence of 6-hydroxydopamine lesion of the dopaminergic nigrostriatal pathway on the muscle tone and electromyographic activity measured during passive movements","volume":"74","author":"Wolfarth","year":"1996","journal-title":"Neuroscience"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0165-0270(96)02211-X","article-title":"Pole test is a useful method for evaluating the mouse movement disorder caused by striatal dopamine depletion","volume":"73","author":"Matsuura","year":"1997","journal-title":"J. Neurosci. Methods"},{"key":"ref_126","doi-asserted-by":"crossref","unstructured":"Rosa, I., Di Censo, D., Ranieri, B., Di Giovanni, G., Scarnati, E., Alecci, M., Galante, A., and Florio, T.M. (2020). Comparison between tail suspension swing test and standard rotation test in revealing early motor behavioral changes and neurodegeneration in 6-OHDA hemiparkinsonian rats. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21082874"},{"key":"ref_127","doi-asserted-by":"crossref","unstructured":"Chuang, C.-S., Su, H.-L., Cheng, F.-C., Hsu, S.-H., Chuang, C.-F., and Liu, C.-S. (2010). Quantitative evaluation of motor function before and after engraftment of dopaminergic neurons in a rat model of Parkinson\u2019s disease. J. Biomed. Sci., 17.","DOI":"10.1186\/1423-0127-17-9"},{"key":"ref_128","doi-asserted-by":"crossref","unstructured":"Wang, X.H., Lu, G., Hu, X., Tsang, K.S., Kwong, W.H., Wu, F.X., Meng, H.W., Jiang, S., Liu, S.W., and Ng, H.K. (2012). Quantitative assessment of gait and neurochemical correlation in a classical murine model of Parkinson\u2019s disease. BMC Neurosci., 13.","DOI":"10.1186\/1471-2202-13-142"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1006\/exnr.1998.6819","article-title":"Characterization of Enhanced Behavioral Responses to L-DOPA Following Repeated Administration in the 6-Hydroxydopamine-Lesioned Rat Model of Parkinson\u2019s Disease","volume":"151","author":"Henry","year":"1998","journal-title":"Exp. Neurol."},{"key":"ref_130","first-page":"2694","article-title":"L-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin-and glutamic acid decarboxylase mRNA","volume":"10","author":"Cenci","year":"1998","journal-title":"Eur. J. Neurosci."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1002\/mds.10588","article-title":"Embryonic mesencephalic grafts increase levodopa-induced forelimb hyperkinesia in Parkinsonian rats","volume":"18","author":"Collier","year":"2003","journal-title":"Mov. Disord."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.neuroscience.2013.01.060","article-title":"BDNF receptor blockade hinders the beneficial effects of exercise in a rat model of Parkinson\u2019s disease","volume":"237","author":"Real","year":"2013","journal-title":"Neuroscience"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1177\/0271678X17750351","article-title":"Evaluation of exercise-induced modulation of glial activation and dopaminergic damage in a rat model of Parkinson\u2019s disease using [11C]PBR28 and [18F]FDOPA PET","volume":"39","author":"Real","year":"2019","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"ref_134","doi-asserted-by":"crossref","unstructured":"De Castro Medeiros, D., Plewnia, C., Mendes, R.V., Pisan\u00f2, C.A., Boi, L., Moraes, M.F.D., Aguiar, C.L., and Fisone, G.A. (2023). A mouse model of sleep disorders in Parkinson\u2019s disease showing distinct effects of dopamine D2-like receptor activation. Prog. Neurobiol., 231.","DOI":"10.1016\/j.pneurobio.2023.102536"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"295","DOI":"10.33549\/physiolres.933995","article-title":"Gastrointestinal non-motor dysfunction in Parkinson\u2019s disease model rats with 6-hydroxydopamine","volume":"68","author":"Feng","year":"2019","journal-title":"Physiol. Res."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/j.pnpbp.2010.06.004","article-title":"Depressive-like behaviors alterations induced by intranigral MPTP, 6-OHDA, LPS and rotenone models of Parkinson\u2019s disease are predominantly associated with serotonin and dopamine","volume":"34","author":"Santiago","year":"2010","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"3863","DOI":"10.1523\/JNEUROSCI.15-05-03863.1995","article-title":"Forelimb Akinesia in the Rat Parkinson Model: Differential Effects of Dopamine Agonists and Nigral Transplants as Assessed by a New Stepping Test","volume":"15","author":"Olsson","year":"1995","journal-title":"J. Neurosci."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"2112146","DOI":"10.1155\/2022\/2112146","article-title":"Effect of Different MPTP Administration Intervals on Mouse Models of Parkinson\u2019s Disease","volume":"2022","author":"Ma","year":"2022","journal-title":"Contrast Media Mol. Imaging"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.expneurol.2013.09.014","article-title":"Modeling Parkinson\u2019s disease in monkeys for translational studies, a critical analysis","volume":"256","author":"Potts","year":"2014","journal-title":"Exp. Neurol."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/jnc.15699","article-title":"Neurochemical, histological, and behavioral profiling of the acute, sub-acute, and chronic MPTP mouse model of Parkinson\u2019s disease","volume":"164","author":"Santoro","year":"2023","journal-title":"J. Neurochem."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.expneurol.2009.05.017","article-title":"Stepping test in mice: A reliable approach in determining forelimb akinesia in MPTP-induced Parkinsonism","volume":"219","author":"Blume","year":"2009","journal-title":"Exp. Neurol."},{"key":"ref_142","first-page":"435","article-title":"A simple quantitative bradykinesia test in MPTP-treated mice","volume":"50","author":"Ogawa","year":"1985","journal-title":"Res. Commun. Chem. Pathol. Pharmacol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.brainres.2009.09.103","article-title":"Vertical grid test and modified horizontal grid test are sensitive methods for evaluating motor dysfunctions in the MPTP mouse model of Parkinson\u2019s disease","volume":"1306","author":"Kim","year":"2010","journal-title":"Brain Res."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.bbr.2005.04.011","article-title":"Swim-test as a function of motor impairment in MPTP model of Parkinson\u2019s disease: A comparative study in two mouse strains","volume":"163","author":"Haobam","year":"2005","journal-title":"Behav. Brain Res."},{"key":"ref_145","doi-asserted-by":"crossref","unstructured":"Lima, M.M.S., Andersen, M.L., Reksidler, A.B., Vital, M.A.B.F., and Tufik, S. (2007). The role of the substantia nigra pars compacta in regulating sleep patterns in rats. PLoS ONE, 2.","DOI":"10.1371\/journal.pone.0000513"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1007\/s11064-018-2620-x","article-title":"Intestinal Pathology and Gut Microbiota Alterations in a Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) Mouse Model of Parkinson\u2019s Disease","volume":"43","author":"Lai","year":"2018","journal-title":"Neurochem. Res."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s40035-023-00368-8","article-title":"Animal models of Parkinson\u2019s disease: Bridging the gap between disease hallmarks and research questions","volume":"12","author":"Dovonou","year":"2023","journal-title":"Transl. Neurodegener."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.bbr.2012.03.008","article-title":"Repeated treatment with a low dose of reserpine as a progressive model of Parkinson\u2019s disease","volume":"231","author":"Fernandes","year":"2012","journal-title":"Behav. Brain Res."},{"key":"ref_149","doi-asserted-by":"crossref","unstructured":"Leal, P.C., Lins, L.C.R.F., de Gois, A.M., Marchioro, M., and Santos, J.R. (2016). Commentary: Evaluation of models of Parkinson\u2019s disease. Front. Neurosci., 10.","DOI":"10.3389\/fnins.2016.00283"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.bbr.2019.01.041","article-title":"Sex differences in the progressive model of parkinsonism induced by reserpine in rats","volume":"363","author":"Bispo","year":"2019","journal-title":"Behav. Brain Res."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.bbr.2013.06.031","article-title":"Cognitive, motor and tyrosine hydroxylase temporal impairment in a model of parkinsonism induced by reserpine","volume":"253","author":"Santos","year":"2013","journal-title":"Behav. Brain Res."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1093\/sleep\/30.4.413","article-title":"Interleukin-1beta mediates sleep alteration in rats with rotenone-induced parkinsonism","volume":"30","author":"Yi","year":"2007","journal-title":"Sleep"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s12640-013-9454-8","article-title":"Antidepressant-like effect of tetrahydroisoquinoline amines in the animal model of depressive disorder induced by repeated administration of a low dose of reserpine: Behavioral and neurochemical studies in the rat","volume":"26","author":"Michaluk","year":"2014","journal-title":"Neurotox. Res."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1111\/1440-1681.13563","article-title":"Myrtenol complexed with \u03b2-cyclodextrin ameliorates behavioural deficits and reduces oxidative stress in the reserpine-induced animal model of Parkinsonism","volume":"48","author":"Silva","year":"2021","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2478\/acph-2022-0008","article-title":"Application of neurotoxin- And pesticide-induced animal models of Parkinson\u2019s disease in the evaluation of new drug delivery systems","volume":"72","author":"Casanova","year":"2022","journal-title":"Acta Pharm."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.expneurol.2004.01.023","article-title":"Behavioral and immunohistochemical effects of chronic intravenous and subcutaneous infusions of varying doses of rotenone","volume":"187","author":"Fleming","year":"2004","journal-title":"Exp. Neurol."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.2174\/1570159X21666230216101659","article-title":"Selecting the Best Animal Model of Parkinson\u2019s Disease for Your Research Purpose: Insight from in vivo PET Imaging Studies","volume":"21","author":"Real","year":"2023","journal-title":"Curr. Neuropharmacol."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.neuro.2018.02.013","article-title":"Rotenone induces gastrointestinal pathology and microbiota alterations in a rat model of Parkinson\u2019s disease","volume":"65","author":"Johnson","year":"2018","journal-title":"Neurotoxicology"},{"key":"ref_159","doi-asserted-by":"crossref","unstructured":"Dodiya, H.B., Forsyth, C.B., Voigt, R.M., Engen, P.A., Patel, J., Shaikh, M., Green, S.J., Naqib, A., Roy, A., and Kordower, J.H. (2020). Chronic stress-induced gut dysfunction exacerbates Parkinson\u2019s disease phenotype and pathology in a rotenone-induced mouse model of Parkinson\u2019s disease. Neurobiol. Dis., 135.","DOI":"10.1016\/j.nbd.2018.12.012"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"e183","DOI":"10.1111\/nmo.12070","article-title":"Effects of oral administration of rotenone on gastrointestinal functions in mice","volume":"25","author":"Tasselli","year":"2013","journal-title":"Neurogastroenterol. Motil."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1111\/j.1476-5381.2011.01426.x","article-title":"Themed Issue: Translational Neuropharmacology-Using Appropriate Animal Models to Guide Clinical Drug Development Animal models of Parkinson\u2019s disease: A source of novel treatments and clues to the cause of the disease","volume":"164","author":"Duty","year":"2011","journal-title":"Br. J. Pharmacol."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"298","DOI":"10.20473\/jfiki.v9i32022.298-304","article-title":"Assessing the Neurotoxicological Effect of the Acute Paraquat Aerosols Exposure in Causing Parkinsonism on Mouse through Behavioral Assays","volume":"9","author":"Maulana","year":"2022","journal-title":"J. Farm. Dan Ilmu Kefarmasian Indones."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1152\/ajpgi.00076.2019","article-title":"Altered gastric tone and motility response to brain-stem dopamine in a rat model of parkinsonism","volume":"317","author":"Bove","year":"2019","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.neuroscience.2015.10.021","article-title":"The impact of combined administration of paraquat and maneb on motor and non-motor functions in the rat","volume":"311","author":"Tinakoua","year":"2015","journal-title":"Neuroscience"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s13311-021-01169-5","article-title":"Rapid Induction of Dopaminergic Neuron Loss Accompanied by Lewy Body-Like Inclusions in A53T BAC-SNCA Transgenic Mice","volume":"19","author":"Okuda","year":"2022","journal-title":"Neurotherapeutics"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"3374","DOI":"10.1093\/brain\/awaa283","article-title":"Propagated a-synucleinopathy recapitulates REM sleep behaviour disorder followed by parkinsonian phenotypes in mice","volume":"143","author":"Shen","year":"2020","journal-title":"Brain"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.nbd.2018.01.008","article-title":"Induction of alpha-synuclein pathology in the enteric nervous system of the rat and non-human primate results in gastrointestinal dysmotility and transient CNS pathology","volume":"112","author":"Manfredsson","year":"2018","journal-title":"Neurobiol. Dis."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.neuron.2019.05.035","article-title":"Transneuronal Propagation of Pathologic \u03b1-Synuclein from the Gut to the Brain Models Parkinson\u2019s Disease","volume":"103","author":"Kim","year":"2019","journal-title":"Neuron"},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.neuron.2005.01.041","article-title":"Nigrostriatal dopaminergic deficits and hypokinesia caused by inactivation of the familial parkinsonism-linked gene DJ-1","volume":"45","author":"Goldberg","year":"2005","journal-title":"Neuron"},{"key":"ref_170","doi-asserted-by":"crossref","unstructured":"Peng, Q., Zhong, S., Tan, Y., Zeng, W.Q., Wang, J., Cheng, C., Yang, X., Wu, Y., Cao, X., and Xu, Y. (2019). The Rodent Models of Dyskinesia and Their Behavioral Assessment. Front. Neurol., 10.","DOI":"10.3389\/fneur.2019.01016"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.bbr.2017.10.036","article-title":"Characterization of oromotor and limb motor dysfunction in the DJ1-\/- model of Parkinson disease","volume":"339","author":"Yang","year":"2018","journal-title":"Behav. Brain Res."},{"key":"ref_172","doi-asserted-by":"crossref","unstructured":"Zhou, W., Barkow, J.C., and Freed, C.R. (2017). Running wheel exercise reduces \u03b1-synuclein aggregation and improves motor and cognitive function in a transgenic mouse model of Parkinson\u2019s disease. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0190160"},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.nbd.2014.06.009","article-title":"Phenotypic characterization of recessive gene knockout rat models of Parkinson\u2019s disease","volume":"70","author":"Dave","year":"2014","journal-title":"Neurobiol. Dis."},{"key":"ref_174","doi-asserted-by":"crossref","unstructured":"Bastioli, G., Regoni, M., Cazzaniga, F., De Luca, C.M.G., Bistaffa, E., Zanetti, L., Moda, F., Valtorta, F., and Sassone, J. (2021). Animal models of autosomal recessive parkinsonism. Biomedicines, 9.","DOI":"10.3390\/biomedicines9070812"},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1523\/JNEUROSCI.4354-07.2008","article-title":"Neuroaxonal dystrophy caused by group VIA phospholipase A2 deficiency in mice: A model of human neurodegenerative disease","volume":"28","author":"Shinzawa","year":"2008","journal-title":"J. Neurosci."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"531","DOI":"10.3233\/JPD-140374","article-title":"Sleep dysfunction and EEG alterations in mice overexpressing alpha-synuclein","volume":"4","author":"McDowell","year":"2014","journal-title":"J. Parkinson\u2019s Dis."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"e81453","DOI":"10.7554\/eLife.81453","article-title":"A prebiotic diet modulates microglial states and motor deficits in \u03b1-synuclein overexpressing mice","volume":"11","author":"Schlachetzki","year":"2022","journal-title":"eLife"},{"key":"ref_178","doi-asserted-by":"crossref","unstructured":"Chen, Y.H., Wang, V., Huang, E.Y.K., Chou, Y.C., Kuo, T.T., Olson, L., and Hoffer, B.J. (2019). Delayed Dopamine Dysfunction and Motor Deficits in Female Parkinson Model Mice. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20246251"},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"e1175","DOI":"10.7717\/peerj.1175","article-title":"A novel biomechanical analysis of gait changes in the MPTP mouse model of Parkinson\u2019s disease","volume":"2015","author":"Geldenhuys","year":"2015","journal-title":"PeerJ"},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.bbr.2004.09.002","article-title":"Age and gender differences in behavioral and morphological outcome after 6-hydroxydopamine-induced lesion of the substantia nigra in rats","volume":"158","author":"Lubics","year":"2005","journal-title":"Behav. Brain Res."},{"key":"ref_181","doi-asserted-by":"crossref","unstructured":"Lima, A.C., Meurer, Y.S.R., Bioni, V.S., Cunha, D.M.G., Gon\u00e7alves, N., Lopes-Silva, L.B., Becegato, M., Soares, M.B.L., Marinho, G.F., and Santos, J.R. (2021). Female Rats Are Resistant to Cognitive, Motor and Dopaminergic Deficits in the Reserpine-Induced Progressive Model of Parkinson\u2019s Disease. Front. Aging Neurosci., 13.","DOI":"10.3389\/fnagi.2021.757714"},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"132","DOI":"10.22270\/ajprd.v11i3.1271","article-title":"An Overview of Animal Models and Symptomatic Treatment of Parkinson\u2019s disease","volume":"11","author":"Patil","year":"2023","journal-title":"Asian J. Pharm. Res. Dev."},{"key":"ref_183","doi-asserted-by":"crossref","unstructured":"Magno, L.A.V., Collodetti, M., Tenza-Ferrer, H., and Romano-Silva, M.A. (2019). Cylinder test to assess sensory-motor function in a mouse model of parkinson s disease. Bio-Protocol, 9.","DOI":"10.21769\/BioProtoc.3337"},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.bbr.2008.12.007","article-title":"Walking pattern analysis after unilateral 6-OHDA lesion and transplantation of foetal dopaminergic progenitor cells in rats","volume":"199","author":"Klein","year":"2009","journal-title":"Behav. Brain Res."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"14524","DOI":"10.1073\/pnas.172514599","article-title":"Resistance of alpha-synuclein null mice to the parkinsonian neurotoxin MPTP","volume":"99","author":"Dauer","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.tins.2018.09.007","article-title":"Triggers, Facilitators, and Aggravators: Redefining Parkinson\u2019s Disease Pathogenesis","volume":"42","author":"Johnson","year":"2019","journal-title":"Trends Neurosci."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1007\/s00415-010-5465-z","article-title":"Frequency of dementia, depression, and other neuropsychiatric symptoms in 1,449 outpatients with Parkinson\u2019s disease","volume":"257","author":"Riedel","year":"2010","journal-title":"J. Neurol."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1212\/WNL.0000000000001609","article-title":"Potential sex differences in nonmotor symptoms in early drug-naive Parkinson disease","volume":"84","author":"Liu","year":"2015","journal-title":"Neurology"},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.smrv.2015.02.005","article-title":"Modeling sleep alterations in Parkinson\u2019s disease: How close are we to valid translational animal models?","volume":"25","author":"Fifel","year":"2016","journal-title":"Sleep Med. Rev."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.pbb.2008.07.014","article-title":"Behavioral responses of dopamine \u03b2-hydroxylase knockout mice to modafinil suggest a dual noradrenergic-dopaminergic mechanism of action","volume":"91","author":"Mitchell","year":"2008","journal-title":"Pharmacol. Biochem. Behav."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.pbb.2004.05.008","article-title":"Altered sleep latency and arousal regulation in mice lacking norepinephrine","volume":"78","author":"Hunsley","year":"2004","journal-title":"Pharmacol. Biochem. Behav."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/S0006-8993(01)03402-3","article-title":"Mesolimbic dopaminergic system is involved in diurnal blood pressure regulation","volume":"928","author":"Sakata","year":"2002","journal-title":"Brain Res."},{"key":"ref_193","doi-asserted-by":"crossref","unstructured":"De Castro Medeiros, D., Aguiar, C.L., Moraes, M.F.D., and Fisone, G. (2019). Sleep Disorders in Rodent Models of Parkinson\u2019s Disease. Front. Pharmacol., 10.","DOI":"10.3389\/fphar.2019.01414"},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"8103","DOI":"10.1523\/JNEUROSCI.1495-09.2009","article-title":"Nonmotor symptoms of Parkinson\u2019s disease revealed in an animal model with reduced monoamine storage capacity","volume":"29","author":"Taylor","year":"2009","journal-title":"J. Neurosci."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.bbi.2018.02.005","article-title":"Neuroprotective effects of fecal microbiota transplantation on MPTP-induced Parkinson\u2019s disease mice: Gut microbiota, glial reaction and TLR4\/TNF-\u03b1 signaling pathway","volume":"70","author":"Sun","year":"2018","journal-title":"Brain Behav. Immun."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"G1013","DOI":"10.1152\/ajpgi.00258.2014","article-title":"Gastric dysregulation induced by microinjection of 6-OHDA in the substantia nigra pars compacta of rats is determined by alterations in the brain-gut axis","volume":"307","author":"Toti","year":"2014","journal-title":"Am. J. Physiol.-Gastrointest. Liver Physiol."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1016\/j.cell.2016.11.018","article-title":"Gut Microbiota Regulate Motor Deficits and Neuroinflammation in a Model of Parkinson\u2019s Disease","volume":"167","author":"Sampson","year":"2016","journal-title":"Cell"},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.expneurol.2015.09.002","article-title":"Depressive-like phenotype induced by AAV-mediated overexpression of human \u03b1-synuclein in midbrain dopaminergic neurons","volume":"273","author":"Caudal","year":"2015","journal-title":"Exp. Neurol."},{"key":"ref_199","doi-asserted-by":"crossref","unstructured":"Chia, S.J., Tan, E.K., and Chao, Y.X. (2020). Historical perspective: Models of Parkinson\u2019s disease. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21072464"},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bbr.2010.03.004","article-title":"Behavioral phenotyping of mouse models of Parkinson\u2019s disease","volume":"211","author":"Taylor","year":"2010","journal-title":"Behav. Brain Res."},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1002\/mds.21010","article-title":"Behavioral models of Parkinson\u2019s disease in rodents: A new look at an old problem","volume":"21","author":"Meredith","year":"2006","journal-title":"Mov. Disord."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.nbd.2011.12.040","article-title":"Animal models of the non-motor features of Parkinson\u2019s disease","volume":"46","author":"McDowell","year":"2012","journal-title":"Neurobiol. Dis."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1136\/jnnp-2019-322338","article-title":"Parkinson\u2019s disease: Etiopathogenesis and treatment","volume":"91","author":"Jankovic","year":"2020","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1001\/jama.2014.3654","article-title":"Pharmacological treatment of Parkinson disease: A review","volume":"311","author":"Connolly","year":"2014","journal-title":"JAMA"},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1002\/mds.21308","article-title":"Rat model of Parkinson\u2019s disease with bilateral motor abnormalities, reversible with levodopa, and dyskinesias","volume":"22","author":"Henry","year":"2007","journal-title":"Mov. Disord."},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/S0014-4886(03)00159-6","article-title":"The effects of chronic L-DOPA therapy on pharmacodynamic parameters in a rat model of motor response fluctuations","volume":"184","author":"Lee","year":"2003","journal-title":"Exp. Neurol."},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/0014-2999(92)90024-X","article-title":"Biochemical and pharmacological studies on pramipexole, a potent and selective dopamine D2 receptor agonist","volume":"215","author":"Mierau","year":"1992","journal-title":"Eur. J. Pharmacol."},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0014-2999(97)00066-6","article-title":"The behavioural effects of pramipexole, a novel dopamine receptor agonist","volume":"324","author":"Maj","year":"1997","journal-title":"Eur. J. Pharmacol."},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.ijpharm.2011.07.029","article-title":"An effective novel delivery strategy of rasagiline for Parkinson\u2019s disease","volume":"419","author":"Negro","year":"2011","journal-title":"Int. J. Pharm."},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1007\/s00415-022-10963-w","article-title":"Levodopa-induced dyskinesia: A historical review of Parkinson\u2019s disease, dopamine, and modern advancements in research and treatment","volume":"269","author":"Hansen","year":"2022","journal-title":"J. Neurol."},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s100720170054","article-title":"Amantadine for dyskinesia in patients affected by severe Parkinson\u2019s disease","volume":"22","author":"Paci","year":"2001","journal-title":"Neurol. Sci."},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1007\/s00702-018-1869-1","article-title":"Efficacy and safety of amantadine for the treatment of L-DOPA-induced dyskinesia","volume":"125","author":"Rascol","year":"2018","journal-title":"J. Neural Transm."},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.expneurol.2004.10.008","article-title":"Early administration of entacapone prevents levodopa-induced motor fluctuations in hemiparkinsonian rats","volume":"192","author":"Marin","year":"2005","journal-title":"Exp. Neurol."},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1212\/01.WNL.0000110317.52453.6C","article-title":"Clozapine improves dyskinesias in Parkinson disease: A double-blind, placebo-controlled study","volume":"62","author":"Durif","year":"2004","journal-title":"Neurology"},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1046\/j.0953-816x.2001.01843.x","article-title":"Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson\u2019s disease","volume":"15","author":"Lundblad","year":"2002","journal-title":"Eur. J. Neurosci."},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1212\/WNL.59.5.706","article-title":"The impact on Parkinson\u2019s disease of electrical parameter settings in STN stimulation","volume":"59","author":"Moro","year":"2002","journal-title":"Neurology"},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S1474-4422(02)00101-1","article-title":"Deep brain stimulation for Parkinson\u2019s disease: Disrupting the disruption","volume":"1","author":"Lozano","year":"2002","journal-title":"Lancet Neurol."},{"key":"ref_218","doi-asserted-by":"crossref","unstructured":"Temel, Y. (2013). Deep Brain Stimulation in Animal Models, Elsevier B.V.. [1st ed.].","DOI":"10.1016\/B978-0-444-53497-2.00002-4"},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1038\/1801200a0","article-title":"3,4-Dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists","volume":"180","author":"Carlsson","year":"1957","journal-title":"Nature"},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1056\/NEJM196702162760703","article-title":"Aromatic amino acids and modification of parkinsonism","volume":"276","author":"Cotzias","year":"1967","journal-title":"N. Engl. J. Med."},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/S1474-4422(21)00249-0","article-title":"Amantadine in the treatment of Parkinson\u2019s disease and other movement disorders","volume":"20","author":"Rascol","year":"2021","journal-title":"Lancet Neurol."},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"915","DOI":"10.2165\/11310890-000000000-00000","article-title":"Of mice and men: Bridging the translational disconnect in CNS drug discovery","volume":"23","author":"Geerts","year":"2009","journal-title":"CNS Drugs"},{"key":"ref_223","doi-asserted-by":"crossref","unstructured":"Zeiss, C.J., Allore, H.G., and Beck, A.P. (2017). Established patterns of animal study design undermine translation of disease-modifying therapies for Parkinson\u2019s disease. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0171790"},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1111\/j.1476-5381.2010.00872.x","article-title":"Animal research: Reporting in vivo experiments: The ARRIVE guidelines","volume":"160","author":"Kilkenny","year":"2010","journal-title":"Br. J. Pharmacol."},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/nrd4090","article-title":"Trial Watch: Phase II and Phase III attrition rates 2011\u20132012","volume":"12","author":"Arrowsmith","year":"2013","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_226","doi-asserted-by":"crossref","unstructured":"Hartung, T. (2024). The (misleading) role of animal models in drug development. Front. Drug Discov., 4.","DOI":"10.3389\/fddsv.2024.1355044"},{"key":"ref_227","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1002\/mds.22712","article-title":"Launching invasive, first-in-human trials against Parkinson\u2019s disease: Ethical considerations","volume":"24","author":"Kimmelman","year":"2009","journal-title":"Mov. Disord."},{"key":"ref_228","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1038\/nrclinonc.2013.171","article-title":"Reproducibility of research and preclinical validation: Problems and solutions","volume":"10","author":"Pusztai","year":"2013","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_229","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1212\/WNL.51.2_Suppl_2.S25","article-title":"Classification of fluctuations in patients with Parkinson\u2019s disease","volume":"51","author":"Quinn","year":"1998","journal-title":"Neurology"},{"key":"ref_230","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1002\/mds.20459","article-title":"Pathophysiology of motor fluctuations in Parkinson\u2019s disease","volume":"20","author":"Widnell","year":"2005","journal-title":"Mov. Disord."},{"key":"ref_231","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/0006-8993(94)90796-X","article-title":"Motor fluctuations in levodopa treated parkinsonian rats: Relation to lesion extent and treatment duration","volume":"662","author":"Papa","year":"1994","journal-title":"Brain Res."},{"key":"ref_232","doi-asserted-by":"crossref","unstructured":"Kwon, D.K., Kwatra, M., Wang, J., and Ko, H.S. (2022). Levodopa-Induced Dyskinesia in Parkinson\u2019s Disease: Pathogenesis and Emerging Treatment Strategies. Cells, 11.","DOI":"10.3390\/cells11233736"},{"key":"ref_233","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/S1474-4422(10)70218-0","article-title":"Levodopa-induced dyskinesias in patients with Parkinson\u2019s disease: Filling the bench-to-bedside gap","volume":"9","author":"Calabresi","year":"2010","journal-title":"Lancet Neurol."},{"key":"ref_234","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.neuroscience.2012.03.023","article-title":"Animal models of l-DOPA-induced dyskinesia: An update on the current options","volume":"211","author":"Iderberg","year":"2012","journal-title":"Neuroscience"},{"key":"ref_235","first-page":"5735082","article-title":"Comparison of basal and hypoxic respiratory behaviors in 6-OHDA and rotenone induced SN lesion Parkinson\u2019s disease rat models","volume":"38","author":"Wadolowski","year":"2023","journal-title":"Physiol. Am. Physiol. Soc."},{"key":"ref_236","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.bbr.2006.02.030","article-title":"Levodopa-induced dyskinesia and rotational behavior in hemiparkinsonian rats: Independent features or components of the same phenomenon?","volume":"170","author":"Konitsiotis","year":"2006","journal-title":"Behav. Brain Res."},{"key":"ref_237","doi-asserted-by":"crossref","first-page":"S59","DOI":"10.1016\/S1353-8020(09)70782-5","article-title":"Plastic effects of L-DOPA treatment in the basal ganglia and their relevance to the development of dyskinesia","volume":"15","author":"Cenci","year":"2009","journal-title":"Park. Relat. Disord."},{"key":"ref_238","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3233\/JPD-181525","article-title":"The Amphetamine Induced Rotation Test: A Re-Assessment of Its Use as a Tool to Monitor Motor Impairment and Functional Recovery in Rodent Models of Parkinson\u2019s Disease","volume":"9","author":"Dunnett","year":"2019","journal-title":"J. Parkinson\u2019s Dis."},{"key":"ref_239","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1002\/mds.27337","article-title":"Animal models of l-dopa-induced dyskinesia in Parkinson\u2019s disease","volume":"33","author":"Cenci","year":"2018","journal-title":"Mov. Disord."},{"key":"ref_240","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.nbd.2007.03.013","article-title":"Chronic 3,4-dihydroxyphenylalanine treatment induces dyskinesia in aphakia mice, a novel genetic model of Parkinson\u2019s disease","volume":"27","author":"Ding","year":"2007","journal-title":"Neurobiol. Dis."},{"key":"ref_241","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1007\/s40263-012-0016-z","article-title":"Targeting glutamate receptors to tackle the pathogenesis, clinical symptoms and levodopa-induced dyskinesia associated with Parkinson\u2019s disease","volume":"26","author":"Duty","year":"2012","journal-title":"CNS Drugs"},{"key":"ref_242","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1136\/jnnp.2008.154948","article-title":"Therapeutic efficacy of unilateral subthalamotomy in Parkinson\u2019s disease: Results in 89 patients followed for up to 36 months","volume":"80","author":"Alvarez","year":"2009","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_243","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1002\/mds.27115","article-title":"Past, present, and future of Parkinson\u2019s disease: A special essay on the 200th Anniversary of the Shaking Palsy","volume":"32","author":"Obeso","year":"2017","journal-title":"Mov. Disord."},{"key":"ref_244","doi-asserted-by":"crossref","first-page":"109687","DOI":"10.1016\/j.jneumeth.2022.109687","article-title":"Parkinson\u2019s disease rodent models: Are they suitable for DBS research?","volume":"380","author":"Mortari","year":"2022","journal-title":"J. Neurosci. Methods"},{"key":"ref_245","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1080\/14737175.2021.1911649","article-title":"Present and future of subthalamotomy in the management of Parkinson\u2019s disease: A systematic review","volume":"21","author":"Obeso","year":"2021","journal-title":"Expert. Rev. Neurother."},{"key":"ref_246","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1590\/S0100-879X2009007500020","article-title":"Lesion of the subthalamic nucleus reverses motor deficits but not death of nigrostriatal dopaminergic neurons in a rat 6-hydroxydopamine-lesion model of Parkinson\u2019s disease","volume":"43","author":"Rizelio","year":"2010","journal-title":"Braz. J. Med. Biol. Res."},{"key":"ref_247","doi-asserted-by":"crossref","first-page":"113926","DOI":"10.1016\/j.expneurol.2021.113926","article-title":"Experimental deep brain stimulation in rodent models of movement disorders","volume":"348","author":"Knorr","year":"2022","journal-title":"Exp. Neurol."},{"key":"ref_248","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/S0306-4522(00)00199-8","article-title":"Effect of high-frequency stimulation of the subthalamic nucleus on the neuronal activities of the substantia nigra pars reticulata and ventrolateral nucleus of the thalamus in the rat","volume":"99","author":"Benazzouz","year":"2000","journal-title":"Neuroscience"},{"key":"ref_249","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1007\/s00221-003-1784-y","article-title":"Stimulation-induced inhibition of neuronal firing in human subthalamic nucleus","volume":"156","author":"Filali","year":"2004","journal-title":"Exp. Brain Res."},{"key":"ref_250","doi-asserted-by":"crossref","first-page":"dmm049543","DOI":"10.1242\/dmm.049543","article-title":"Defining the unknowns for cell therapies in Parkinson\u2019s disease","volume":"15","author":"Lane","year":"2022","journal-title":"Dis. Model. Mech."},{"key":"ref_251","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1602\/neurorx.1.4.382","article-title":"Cell Therapy in Parkinson\u2019s Disease","volume":"1","author":"Lindvall","year":"2004","journal-title":"NeuroRx"},{"key":"ref_252","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/j.neurobiolaging.2005.04.010","article-title":"Increased sensitivity to MPTP in human \u03b1-synuclein A30P transgenic mice","volume":"27","author":"Nieto","year":"2006","journal-title":"Neurobiol. Aging"},{"key":"ref_253","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/S0014-4886(03)00342-X","article-title":"Enhanced substantia nigra mitochondrial pathology in human \u03b1-synuclein transgenic mice after treatment with MPTP","volume":"186","author":"Song","year":"2004","journal-title":"Exp. Neurol."},{"key":"ref_254","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.neuro.2004.05.002","article-title":"Mice Lacking \u03b1-Synuclein have an Attenuated Loss of Striatal Dopamine Following Prolonged Chronic MPTP Administration","volume":"25","author":"Drolet","year":"2004","journal-title":"Neurotoxicology"},{"key":"ref_255","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/S0306-4522(03)00036-8","article-title":"Role of \u03b1-synuclein in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonism in mice","volume":"118","author":"Fornai","year":"2003","journal-title":"Neuroscience"},{"key":"ref_256","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.nbd.2005.08.018","article-title":"Mice lacking alpha-synuclein are resistant to mitochondrial toxins","volume":"21","author":"Klivenyi","year":"2006","journal-title":"Neurobiol. Dis."},{"key":"ref_257","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1038\/nature14547","article-title":"\u03b1-Synuclein strains cause distinct synucleinopathies after local and systemic administration","volume":"522","author":"Peelaerts","year":"2015","journal-title":"Nature"},{"key":"ref_258","doi-asserted-by":"crossref","first-page":"15209","DOI":"10.1073\/pnas.2001305117","article-title":"Impact of \u03b1-synuclein pathology on transplanted hESC-derived dopaminergic neurons in a humanized \u03b1-synuclein rat model of PD","volume":"117","author":"Hoban","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_259","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.3233\/JPD-212555","article-title":"Sequential or Simultaneous Injection of Preformed Fibrils and AAV Overexpression of Alpha-Synuclein Are Equipotent in Producing Relevant Pathology and Behavioral Deficits","volume":"12","author":"Negrini","year":"2022","journal-title":"J. Parkinson\u2019s Dis."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/16\/8971\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:38:18Z","timestamp":1760110698000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/16\/8971"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,17]]},"references-count":259,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2024,8]]}},"alternative-id":["ijms25168971"],"URL":"https:\/\/doi.org\/10.3390\/ijms25168971","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,17]]}}}